Managing Bleeding/Oozing in Patients on Hormone Replacement Therapy

Understanding the Cause of Bleeding

Breakthrough bleeding is a common side effect during the first 3-6 months of hormone replacement therapy (HRT), particularly with continuous regimens, according to the Centers for Disease Control and Prevention 2
Continuous daily progesterone can lead to irregular endometrial shedding and persistent spotting or oozing, as reported by the American College of Obstetricians and Gynecologists 1
The current regimen of nightly micronized progesterone may be causing unstable endometrial development, as noted by the European Society of Human Reproduction and Embryology 3

Switching from continuous to sequential regimen, changing from nightly progesterone to 200mg daily for 12-14 consecutive days per 28-day cycle, is recommended by the American College of Obstetricians and Gynecologists 1, 3
For patients with persistent bleeding on continuous HRT, a short 3-4 day hormone-free interval can help regulate bleeding patterns, as suggested by the Centers for Disease Control and Prevention 2

Short-term NSAID therapy for 5-7 days during bleeding episodes is considered by the American College of Obstetricians and Gynecologists 1
Adjusting estrogen dosing to ensure appropriate estradiol patch dosing (typically 50-100 μg/day) to balance with progesterone is recommended by the European Society of Human Reproduction and Embryology 3
Evaluating endometrial thickness using ultrasound assessment if bleeding persists beyond 3-6 months of therapy is suggested by the American College of Obstetricians and Gynecologists 1

Assessing bleeding pattern after 3 months of the modified regimen is recommended by the American College of Obstetricians and Gynecologists 1
Annual clinical review is recommended for patients on HRT by the European Society of Human Reproduction and Embryology 4

Breakthrough bleeding is common in the first 3-6 months of HRT and generally decreases with continued use, as noted by the Centers for Disease Control and Prevention 2
Persistent bleeding beyond 6 months warrants further evaluation to rule out endometrial pathology, according to the American College of Obstetricians and Gynecologists 1
Micronized progesterone is preferred over synthetic progestins due to its better cardiovascular and thrombotic risk profile, as reported by the American College of Obstetricians and Gynecologists 1

For women with endometriosis history, combined estrogen/progesterone therapy can be effective for vasomotor symptoms while reducing disease reactivation risk, as noted by the European Society of Human Reproduction and Embryology 5